A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations, in Subjects With Prostatic Adenocarcinoma.
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2014
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Abbott Laboratories; TAP Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 13 May 2010 Additional trial identifier 1B-08-2 identified as reported by University of Southern California Norris Comprehensive Cancer Center record.
- 13 May 2010 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center record no. 1B-08-2).